High Tide (Nasdaq:HITI) Reports Record Cannabis Distribution Through Remexian Pharma

2026-05-06, 4:09:50 a.m.

CALGARY, AB — May 6, 2026 — Leads & Copy —

High Tide Inc. announced today that its 51%-owned German subsidiary, Remexian Pharma GmbH, sold 7.6 tonnes of medical cannabis into the German market during the second fiscal quarter ended April 30, 2026. This represents the highest quarterly distribution volume in Remexian’s history, with volumes increasing 21% on a sequential basis and 49% year over year.

According to High Tide, the 7.6 tonnes is evidence that their model is scaling in Europe’s largest medical cannabis market. They say this increase is a direct result of pairing a leading German distribution platform with High Tide’s procurement capabilities, built over $2.2 billion of legal cannabis sales in Canada.

Raj Grover, Founder and Chief Executive Officer of High Tide, said that this level of sequential and year-over-year growth reinforces their conviction that Germany is only the beginning. He added that High Tide is building a repeatable, capital-efficient distribution engine that can be expanded across Europe, subject to regulatory conditions, and that the company fully intends to leverage this momentum to continue taking share in Germany while methodically entering additional high-growth markets.

The company reported that Germany imported 201.1 tonnes of medical cannabis in 2025, more than doubling the previous year’s 72.9 tonnes. Almost half of its imports (over 93 tonnes) came from Canada.

High Tide is a retail-forward cannabis enterprise. Its wholly owned subsidiary, Canna Cabana, is the second-largest cannabis retail brand globally. The company’s Canadian bricks-and-mortar operations span British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario, holding a 12% share of the market. In 2025, High Tide became the first North American cannabis operator to launch a bricks-and-mortar presence in Germany.

Remexian Pharma GmbH is a German pharmaceutical company focused on the importation and wholesale of medical cannabis products. Remexian has a market share exceeding 10% of tonnage imported and is licensed to import from 19 countries including Canada.

The preliminary Remexian tonnage figures are unaudited and subject to revision upon completion of the Company’s second fiscal quarter financial statements. The Company will report its complete second fiscal quarter 2026 financial results in June 2026.

Source: High Tide Inc.

×

Welcome!

CannabisReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy

By Subscribing you will receive Daily Cannabis Story Leads via email 10:30 am ET Mon-Fri.